Description: Concert Pharmaceuticals, Inc., a biotechnology company, develops drug candidates. Its drug candidates address various therapeutic areas, including hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, schizophrenia, multiple tumors, and hyperparathyroidism, as well as provide agents for diabetic nephropathy and other forms of chronic kidney diseases. The company also develops CTP-354, a GABA(A) receptor subtype-selective modulator for the treatment of spasticity and chronic pain. Concert Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline plc and Celgene Corporation. The company was founded in 2006 and is based in Lexington, Massachusetts.
Home Page: www.concertpharma.com
CNCE Technical Analysis
65 Hayden Avenue
Lexington,
MA
02421
United States
Phone:
781 860 0045
Officers
| Name | Title |
|---|---|
| Mr. Richard H. Aldrich M.B.A., Mba | Co-Founder & Independent Chairman |
| Dr. Roger D. Tung Ph.D. | Co-Founder, CEO, Pres & Exec. Director |
| Mr. Marc A. Becker | Chief Financial Officer |
| Dr. James V. Cassella Ph.D. | Chief Devel. Officer |
| Ms. Nancy Stuart | Chief Operating Officer |
| Ms. Justine E. Koenigsberg | Sr. VP of Corp. Communications & Investor Relations |
| Mr. Jeffrey A. Munsie | Chief Legal Officer & Corp. Sec. |
| Dr. Nabil Uddin Pharm.D. | VP of Corp. Devel. |
| Ms. Christine Boisclair | Sr. VP of Regulatory Affairs & Quality Assurance |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6654 |
| Price-to-Sales TTM: | 7.0467 |
| IPO Date: | 2014-02-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 64 |